Dynamic of the GRF-induced GH response in genetically obese Zucker rats: influence of central and peripheral factors.
Renier. G G; Gaudreau. P P; Deslauriers. N N; Petitclerc. D D; Brazeau. P P
Key Findings
- Obese rats show normal GH response to GRF at 6 weeks but a marked decline by 8 weeks
- Higher insulin, free fatty acids, and hypothalamic somatostatin are linked to the reduced GH response
- Serum from obese rats suppresses GH release from healthy pituitary cells, indicating peripheral factors matter
Practical Outcomes
- If you’re using sermorelin for anti‑aging or performance, improving insulin sensitivity and reducing excess body fat may be needed for it to work well. Simply taking the peptide while obese might give weaker GH spikes. Consider diet, exercise, or insulin‑sensitizing supplements before or alongside sermorelin.
Summary
In obese Zucker rats, the ability of a growth‑hormone‑releasing peptide (like sermorelin) to boost GH drops sharply by 8 weeks old, likely because high insulin, fatty acids, and brain somatostatin block the response. This suggests that excess body fat and related metabolic issues can blunt the effects of GH‑releasing drugs.
Abstract
To determine the time onset of the growth hormone (GH) alteration in the genetically obese rat, we studied the in vivo and in vitro rat growth hormone releasing factor (rGRF(1-29)NH2)-induced GH secretion in 6- and 8-week-old lean and obese male Zucker rats. Under sodium pentobarbital anesthesia, rGRF(1-29)NH2 (GRF) was injected intravenously at two doses: 0.8 and 4.0 micrograms/kg b.w. Basal serum GH concentrations were similar in lean and obese age-matched animals. The GH response to both GRF doses tested was unchanged in 6-week-old obese rats as compared to their lean litter mates. In contrast, a significant decrease of the GH secretion in response to 4.0 micrograms/kg b.w. GRF was observed in the 8-week-old obese rats. The effect of GRF (1.56, 6.25 and 12.5 pM) was further studied in vitro, in a perifusion system of freshly dispersed anterior pituitary cells of lean and obese Zucker rats. Basal GH release was similar in the 6-week-old animal group. In contrast, it was significantly decreased in 8-week-old obese rats as compared to their lean litter mates. Stimulated GH response to 1.56 and 6.25 pM GRF was significantly greater in the 6-week-old obese group than in the age-matched control group. In contrast, the GH response to all GRF concentrations tested was significantly decreased in the 8-week-old obese rats as compared to their respective lean siblings. In 8-week-old obese rats, a decrease of GH pituitary content and an increase of hypothalamic somatostatin (SRIF) concentration were observed. Insulin and free fatty acid serum were significantly increased in 8-week-old obese rats. In contrast, lower insulin-like growth factor I serum levels were observed in the obese animals as compared to their lean litter mates. Finally, to further clarify the role of the periphery in the inhibition of GH secretion observed in the 8-week-old fatty rats, we exposed cultured pituitary cells of 8-week-old lean animals to 17% serum of their obese litter mates. A significant decrease of GRF-stimulated GH secretion of lean rat pituitary cells exposed to the obese serum was noted (P less than 0.05). This study demonstrates that, in the obese Zucker rat, an alteration of the GH response to GRF is evident by the 8th week of life. This defective GH secretion could be related to peripheral and central abnormalities.
Study Information
pubmed
1990
1990-03-27T00:00:00.000Z
10.1016/0167-0115(90)90067-7
8
14